Dr. Antonarakis on PD-1/PD-L1 Monotherapy in Prostate Cancer

Video

In Partnership With:

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

In a biomarker unselected population, any PD-1 or PD-L1 inhibitor by itself is probably not going to be enough, says Antonarakis. However, single agent use of these inhibitors might be beneficial in certain subsets of patients with the disease, such as those who have mismatch repair deficiency or microsatellite instability—high genotypes. PD-1/PD-L1 monotherapy may also show activity in patients with CDK12 mutations, adds Antonarakis; those with this mutation account for 6% to 7% of all prostate cancer cases. Additionally, some preliminary data that have not yet been confirmed suggest that patients with BRCA1/2 mutations may also be slightly enriched for a response to single-agent PD-1 inhibition, concludes Antonarakis.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD